

PATIENT INFORMATION (PLEASE PRINT IN BLACK INK)

Last Name	First	MI
Address	Birth Date (MM/DD/YYYY)	Sex <input type="checkbox"/> M <input type="checkbox"/> F
City	SS #	International Patient? <input type="checkbox"/> Yes <input type="checkbox"/> No
State	Zip	Home Phone
Hospital/Physician Office Patient ID #	Accession #	

MEDICAL NECESSITY NOTICE: When ordering tests for which Medicare reimbursement will be sought, physicians (or other individuals authorized by law to order tests) should only order tests that are medically necessary for the diagnosis or treatment of a patient, rather than for screening purposes.

INSURANCE BILLING INFORMATION (PLEASE ATTACH CARD OR PRINT IN BLACK INK)

**BILL TO:** ☐ Client/Institution ☐ Medicare ☐ Insurance (Complete insurance information below) ☐ Patient

**PATIENT STATUS:** ☐ Inpatient ☐ Outpatient ☐ Non-Hospital Patient Hospital discharge date: \_\_\_\_/\_\_\_\_/\_\_\_\_  
MM DD YYYY

**PRIMARY:** ☐ Medicare ☐ Medicaid (Ohio only) ☐ Other Ins. \_\_\_\_\_ ☐ Self ☐ Spouse ☐ Child

Subscriber Last Name	First	MI
Beneficiary / Member #	Group #	
Claims Address	City	State Zip

**SECONDARY:** ☐ No ☐ Yes (if Yes, please attach) **ABN:** ☐ No ☐ Yes

**DIAGNOSIS CODE (REQUIRED)** ICD-10 Codes 1. \_\_\_\_\_ 2. \_\_\_\_\_ 3. \_\_\_\_\_

ADDITIONAL CLINICAL INFORMATION

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

CLIENT INFORMATION

ORDERING PHYSICIAN CONTACT

Choose one: ☐ Clinician ☐ Pathologist

Physician Name \_\_\_\_\_

NPI # \_\_\_\_\_

Physician Phone \_\_\_\_\_

Physician Email \_\_\_\_\_

Fax report to: (\_\_\_\_\_) \_\_\_\_\_

Fax additional report to: (\_\_\_\_\_) \_\_\_\_\_

SPECIMEN INFORMATION

Please submit copy of Surgical Pathology report with requisitions

Collection Date (MM/DD/YYYY): \_\_\_\_/\_\_\_\_/\_\_\_\_

Time: \_\_\_\_\_ ☐ AM ☐ PM

Body Site: \_\_\_\_\_ Client Case #: \_\_\_\_\_

Specimen ID: \_\_\_\_\_

☐ Paraffin Cell Blocks: \_\_\_\_\_ ☐ Paraffin Tissue Blocks: \_\_\_\_\_

☐ Slides, unbaked & unstained

Fixation Type: ☐ Formalin ☐ Alcohol ☐ Other: \_\_\_\_\_

**\*\*Decalcified specimens will be rejected.**

**Breast Samples: CAP/ASCO Requirements**

10% neutral buffered formalin: ☐ Yes ☐ No ☐ Unknown

Fixation time >6 and <72 hours: ☐ Yes ☐ No ☐ Unknown

Cold ischemic time ≤ 1 hour: ☐ Yes ☐ No ☐ Unknown

AVAILABLE MOLECULAR AND BIOMARKER TESTING WITH INTERPRETATION:

NEXT-GENERATION SEQUENCING (NGS) PANELS

- ☐ **CC-SIGN® NTRK 1,2,3, by NGS**  
(as part of NTRK Plus Gene Fusion NGS Panel)
- ☐ **CC-SIGN® Targeted Oncology Panel (TOP)** by NGS for pan cancer hotspots, copy number gains & fusions 59 driver genes; refer to TOP Gene List on Test Directory
  - ☐ FFPE *TOP10*
  - ☐ Alcohol- or FFPE-fixed cell blocks *TOPCY*

- OTHER**
- ☐ BRAF V600E by ddPCR *BRAFO*
  - ☐ KIT D816V by ddPCR *K8160*

- BREAST**
- ☐ **CC-SIGN® TOP NGS Panel**  
includes *ESR1/ER, ERBB2/HER2, AKT1, PIK3CA, CCND1, ETV6::NTRK3, MAGI3::AKT3, FGFR2::AFF3* + pan cancer markers
  - ☐ **Breast Markers Profile: ER, PR, HER2 by IHC**  
(reflex to FISH if equivocal)

Immunohistochemistry (select any/all):

- ☐ ER ☐ PR ☐ Androgen Receptor
- ☐ Ki67 ☐ HER2 (reflex to FISH if equivocal)
- ☐ HER2 by FISH (reflex to IHC if Group 2, 3, or 4)
- ☐ Mismatch repair (MMR) by IHC  
(reflex to *MLH1* promoter methylation)

COLORECTAL/SMALL BOWEL

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *BRAF, KRAS, NRAS, PIK3CA, ERBB2/HER2* + pan cancer markers
- ☐ **Metastatic Colorectal/Small Bowel Profile: Mismatch repair (MMR) by IHC** (reflex to *MLH1* promoter methylation), **CC-SIGN TOP NGS Panel**
- ☐ Mismatch repair (MMR) by IHC  
(reflex to *MLH1* promoter methylation)
- ☐ HER2 by IHC (reflex to FISH in equivocal cases)
- ☐ *MLH1* promoter methylation (PCR) *MLH1PH*

ENDOMETRIAL/GYN

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *ERBB2/HER2, PIK3CA, AKT1, CTNNB1, TP53, NTRK* fusions + pan cancer markers
- ☐ Mismatch repair (MMR) by IHC  
(reflex to *MLH1* promoter methylation)
- ☐ ER by IHC ☐ PR by IHC

- ☐ PD-L1 by IHC (Clone 22C3) – for cervical primary only
- ☐ *MLH1* promoter methylation (PCR) *MLH1PH*

GASTROINTESTINAL STROMAL TUMOR

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *BRAF, KIT, PDGFRA* + pan cancer markers

GENITOURINARY

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *AR, TP53, TMPRSS2::ERG, TMPRSS2::ETV1, TMPRSS2::ETV4, TMPRSS2::ETV5, SLC45A3::ERG, SLC45A3::BRAF, FGFR3::TACC3* + pan cancer markers
- ☐ Mismatch repair (MMR) by IHC  
(reflex to *MLH1* promoter methylation)
- ☐ PD-L1 by IHC for pembrolizumab/Keytruda® use (Clone 22C3)

HEAD & NECK AND THYROID

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *BRAF, RAS genes, TP53, pTERT, MET, PIK3CA, RET/ALK/BRAF* fusions, *PAX8::PPARG* + pan cancer markers
- ☐ **CC-SIGN® Head & Neck Gene Fusion NGS Panel**
- ☐ HER2 by IHC (reflex to FISH in equivocal cases)
- ☐ HPV High and Low Risk by *in situ* hybridization
- ☐ HPV High Risk by *in situ* hybridization
- ☐ HPV Low Risk by *in situ* hybridization
- ☐ NUT by IHC
- ☐ PD-L1 by IHC (Clone 22C3)

LUNG

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *BRAF, EGFR, ERBB2/HER2, KRAS, MET, DDR2, MET* exon 14 skipping, *ALK/RET/ROS1* fusions + pan cancer markers
- ☐ **Lung Carcinoma (non-squamous NSCLC) Profile:**  
*ALK D5F3* by IHC (reflex to FISH), *PD-L1* by IHC (Clone 22C3), *ROS1* by FISH, *RET* by FISH, **CC-SIGN TOP NGS Panel**
- ☐ *ALK* (FISH) *FSHLNG*
- ☐ *RET* (FISH) *RET*
- ☐ *ROS* (FISH) *ROS1*
- ☐ *ALK D5F3* by IHC (reflex to FISH)
- ☐ PD-L1 by IHC (Clone 22C3)

LYMPHOMA

- ☐ B-Cell Clonality BIOMED-2 (PCR) (IGH/IGK) *BCBMD0*
- ☐ B-Cell Immunoglobulin Heavy (IGH) Chain BIOMED-2 (PCR) *IGHO*
- ☐ B-Cell Immunoglobulin Kappa (IGK) Chain BIOMED-2 (PCR) *IGKO*
- ☐ T-Cell Clonality (TCRB & TCRG rearrangement) (PCR) *TCBMD0*
- ☐ T-Cell Receptor Beta (TCRB) BIOMED-2 (PCR) *TCRBO*
- ☐ T-Cell Receptor Gamma (TCRG) BIOMED-2 (PCR) *TCRGO*

Immunohistochemistry/CISH (select any/all):

- ☐ CD30 ☐ CD19 ☐ PD-L1 (Clone 22C3)
- ☐ MYC-IHC ☐ CISH EBER
- ☐ FISH (select any/all):
- ☐ **Aggressive B-cell Lymphoma Panel** includes *MYC, BCL2, BCL6, IGH::MYC, t(8;14) FABCEL*
- ☐ *BCL2 BCL2FT* ☐ *BCL6 BCL6FT*
- ☐ *BIRC::MALT T1118* ☐ *IGH::BCL2 T1418*
- ☐ *IGH::CCND1 t(11;14) T1114* ☐ *IGH::MYC T814*
- ☐ *MALT MALTI* ☐ *MYC* amplification *MYCAMP*

MELANOMA

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *BRAF, KIT, NRAS, pTERT* + pan cancer markers
- ☐ BRAF V600E by IHC (reflex to Top NGS Panel if equivocal)
- ☐ Cutaneous Melanoma (FISH) *CMFISH*
- ☐ PD-L1 by IHC (Clone 22C3)

NEURO

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *IDH1/2, H3-3A/B, EGFR, PDGFRA, PIK3CA, EGFR vll, KIAA1549::BRAF, FGFR1/2/3* mutations and fusions + pan cancer markers
- ☐ ATRX by IHC
- ☐ Glioma panel (1p/19q/EGFR) (FISH)
- ☐ 1p/19q (FISH) *1P19Q*
- ☐ EGFR (FISH) *EGFRF*
- ☐ IDH1(R132H) by IHC
- ☐ MGMT Methylation (PCR) *MGMT*
- ☐ SSTR2A by IHC

PANCREATICOBILIARY

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *KRAS, TP53, BRAF, GNAS, NRAS, pTERT, ERBB2/HER2, PIK3CA, FGFR1/2/3, EGFR, NTRK* fusions + pan cancer markers

SOFT TISSUE/SARCOMA

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *MYC* amplification, *KIT, BRAF, PDGFRA, GNAS, GNAQ, GNAI1, H3-3A/B, CTNNB1* + pan cancer markers
- ☐ **CC-SIGN® Solid Tumor Gene Fusion NGS Panel**  
(59 gene panel) – refer to SRCNGS gene list on Test Directory

FISH (select any/all):

- ☐ *DDIT3* (*CHOP/IGL1* (12q13)) *DDIT3* ☐ *EWSR1* (22q12) *EWSR*
- ☐ *FOXO1A* (13q14) *FKHR* ☐ *FUS* (16p11) *FUS*
- ☐ *MDM2* amplification *MDM2*
- ☐ *MYC* amplification (angiosarcoma) *MYCAMP*
- ☐ SS18 (18q11) *SYT*

STOMACH/EGJ

- ☐ **CC-SIGN® TOP NGS Panel**  
includes *TP53, ERBB2/HER2* amplification, *NTRK* fusions + pan cancer markers
- ☐ **Stomach/EGJ Profile: Mismatch repair (MMR) by IHC, HER2 by IHC** (reflex to FISH in equivocal cases), **PD-L1 by IHC** (Clone 22C3)
- ☐ Mismatch repair (MMR) by IHC  
(reflex to *MLH1* promoter methylation)
- ☐ HER2 by IHC (reflex to FISH in equivocal cases)
- ☐ PD-L1 by IHC (Clone 22C3)

OTHER TESTING

- ☐ HPV High and Low Risk by *in situ* hybridization
- ☐ HPV High Risk only by *in situ* hybridization
- ☐ HPV Low Risk only by *in situ* hybridization
- ☐ Microsatellite instability (PCR) *MSICCT*  
must provide normal + tumor representative specimen
- ☐ Mismatch repair (MMR) by IHC  
(reflex to *MLH1* promoter methylation)
- ☐ *MLH1* promoter methylation (PCR) *MLH1PH*

ONCOLOGY FISH: REFER TO ONCOLOGY FISH PROBE LIST

Indicate probe(s): \_\_\_\_\_

FISH Panels

PANEL NAME	Probes included		Accepted Specimen Sources			
	QTY	Target Locations	Blood	Bone Marrow	FFPET	Cell Block*
Aggressive B-Cell Lymphoma	4	BCL2, BCL6, MYC, IGH::MYC	x	x	x	
Acute Myeloid Leukemia	4	PML::RARA, RUNX1::RUNX1T1, CBFβ::MYH11, MLL	x	x		
B Lymphoblastic Leukemia	6	BCR::ABL, CRLF2, CRLF2::IGH, ETV6::RUNX1, MLL, Trisomy 4/10	x	x		
CLL	3	CLL1, CLL2, IGH::CCND1	x			
Cutaneous Melanoma	5	RREB1, CCND1, MYB, MYC, CDKN2A			x	
Glioma	3	1p36, 19q13, EGFR			x	
Myelodysplastic Syndrome	3	5q, 7q, 20q, CEP 8	x	x		
Myeloproliferative Neoplasms	4	BCR::ABL , PDGFRA, PDGFRB, FGFR1	x	x		
Plasma Cell Myeloma	5**	RB1/TP53, CKS1B/CDKN2C, CEP 9/CEP 15, IGH, IGH::CCND1 **Reflex to IGH::MMSET and IGH::MAF if indicated.*		x		
UroVysion	4	CEP 3, CEP 7, CEP 17, 9p21	Thin prep slide			

\*Must be formalin fixed. Alcohol fixed cell blocks will be rejected.

FISH Single Target

PROBE NAME	Chromosomal / Target Location	Blood	Bone Marrow	FFPET	Cell Block*	Thin Prep Slide
1p	1p36			x		
5q	5p15/5q31	x	x			
7q	CEP7/7q31	x	x			
19q	19q13			x		
20q	20q12 <i>Only offered with CEP 8</i>	x	x			
ALK for NSCLC	2p23			x	x	x
BCL2	18q21	x	x	x		
BCL6	3q27	x	x	x		
BCRABL	t(9;22)(q34;q11.2)	x	x			
BIRC3::MALT	t(11;18)(q22;q21)			x		
CBFB::MYH11	16q22-Inversion 16	x	x			
CDKN2A	9p21 <i>Only offered as part of Cutaneous Melanoma &amp; UroVysion Panels</i>			x		x
CCND1	11q13	x	x	x		
CEP 3	Centromere of chromosome 3 <i>Only offered as part of UroVysion Panel</i>					x
CEP 4	Centromere of chromosome 4 <i>Only offered with CEP 10</i>	x	x			
CEP 7	Centromere of chromosome 7 <i>Only offered as part of UroVysion Panel</i>					x
CEP 8	Centromere of chromosome 8 <i>Only offered with 20q</i>	x	x			
CEP 9	Centromere of chromosome 9 <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
CEP 10	Centromere of chromosome 10 <i>Only offered with CEP 4</i>	x	x			
CEP 15	Centromere of chromosome 15 <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
CEP 17	Centromere of chromosome 17 <i>Only offered as part of UroVysion Panel</i>					x

PROBE NAME	Chromosomal / Target Location	Blood	Bone Marrow	FFPET	Cell Block*	Thin Prep Slide
CEP X	Centromere of X chromosome <i>Only offered with CEP Y (DXY3)</i>	x				
CEP Y (DXY3)	Centromere of Y chromosome <i>Only offered with CEP X</i>	x				
CEP Y (DZY1)	Yqh of Y Chromosome	x				
CHOP/DDIT3	12q13			x		
CKS1B/CDKN2C	1p31,q21 <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
CLL1	17p13,11q22 <i>Only offered as part of CLL Panel</i>	x	x			
CLL2	D13S319/CEP 12/13q24 <i>Only offered as part of CLL Panel</i>	x	x			
EGFR	7p11.2			x		
ETV6::RUNX1	t(12;21)(p13;q22)	x	x			
EWSR1	22q12			x		
FGFR1	8p12	x	x			
FOXO1	13q14			x		
FUS	16p11.2			x		
HER2	17q12			x		
IGH	14q23	x	x	x		
IGH::BCL2	t(14;18)(q32;q21)	x	x	x		
IGH::CCND1	t(11;14)(q13;q32)	x	x	x		
IGH::MAF	t(14;16)(q32;q23) <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
IGH::MMSET	t(4;14)(p16q32) <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
IGH::MYC	t(8;14)(q24;q32)	x	x	x		
MALT1	18q21			x		
MDM2	12q15			x		
MLL	11q23	x	x			
MYB	6q23 <i>Only offered as part of Cutaneous Melanoma Panel</i>			x		
MYC-Break apart	8q24	x	x	x		
MYC-Amplification	8q24			x		
PDGFRA	4q12	x	x			
PDGFRB	5q32	x	x			
PML::RARA	t(15;17)(q22;q21)	x	x			
RARA	17q21	x	x			
RB1/TP53	13q/17p <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
RET	10q11.21			x	x	
ROS1	6q22			x	x	
RREB1	6p25 <i>Only offered as part of Cutaneous Melanoma Panel</i>			x		
RUNX1::RUNX1T1	t(8;21)(q21;q22)	x	x			
SRY	Yp11.3	x				
SS18::SYT	t(X;18)(p11;q11)			x		
XIST	Xq13.2	x				

\*Must be formalin fixed. Alcohol fixed cell blocks will be rejected.